Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles
Clinical trial NCT06868017 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06868017
- Sponsor
- The First Hospital of Jilin University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-01
- Primary completion
- 2026-02-19
- Enrollment
- 208
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.